Cargando…
MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells
Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) have improved the survival of patients with non‐small cell lung cancer (NSCLC). Still, many patients do not respond to these inhibitors. PD‐L1 (CD274) expression, one of the factors th...
Autores principales: | Stutvoet, Thijs S, Kol, Arjan, de Vries, Elisabeth GE, de Bruyn, Marco, Fehrmann, Rudolf SN, Terwisscha van Scheltinga, Anton GT, de Jong, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767771/ https://www.ncbi.nlm.nih.gov/pubmed/30972766 http://dx.doi.org/10.1002/path.5280 |
Ejemplares similares
-
(89)Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment
por: Pool, Martin, et al.
Publicado: (2017) -
ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells
por: Kol, Arjan, et al.
Publicado: (2017) -
Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer (89)Zr-imgatuzumab
por: Pool, Martin, et al.
Publicado: (2016) -
(89)Zr-Onartuzumab PET imaging of c-MET receptor dynamics
por: Pool, Martin, et al.
Publicado: (2017) -
Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with (89)Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts
por: ter Weele, Eva J., et al.
Publicado: (2015)